CALLISTO PHARMACEUTICALS (GREY:CLSP)

Callisto Pharmaceuticals, Inc. (Callisto), incorporated in May 2003, is a development-stage biopharmaceutical company focused primarily on the development of drugs to treat neuroendocrine cancer (including advanced carcinoid cancer), rheumatoid arthritis (RA), acute leukemia and gastrointestinal (GI) disorders and diseases. The Company’s drug candidates include SP-304, a guanylyl cyclase C (GC-C) receptor agonist, to treat GI disorders, primarily chronic constipation (CC) and constipation-predominant irritable bowel syndrome (IBS-C); SP-333, a second generation GC-C receptor agonist; Atiprimod is an orally administered drug with antiproliferative, anti-inflammatory and antiangiogenic activity, and L-Annamycin is a compound from the anthracycline family of anti-cancer drugs, which has therapeutic profile, including activity against drug resistant tumors. The Company operates through two subsidiary companies: Synergy Pharmaceuticals Inc. and Callisto Research Labs, LLC.